Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and Dogs

3 Mar 2020

Abstract excerpt

Cyclic adenosine monophosphate-response element (CREB)-binding protein (CBP) and EP300E1A-binding protein (p300) are members of the bromodomain and extraterminal motif (BET) family. These highly homologous proteins have a key role in modulating transcription, including altering the status of chromatin or through interactions with or posttranslational modifications of transcription factors. As CBP and p300 have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32124659
DOI: 10.1177/0192623319898469

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and DogsPMID 32124659Read ↗

Characteristics of anticancer activity of CBP/p300 inhibitors – Features of their classes, intracellular targets and future perspectives of their application in cancer treatmentSemantic proximity Read ↗

Genetic mutations and inhibitors of p300 and CBP.Semantic proximity Read ↗

Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor ActivitySemantic proximity Read ↗

Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734Semantic proximity Read ↗

Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal.Semantic proximity Read ↗

Clinical progress and pharmacology of small molecule bromodomain inhibitorsSemantic proximity Read ↗

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignanciesSemantic proximity Read ↗

GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) ProteinsSemantic proximity Read ↗

Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.Semantic proximity Read ↗

Chemical and genetic rescue of an ep300 knockdown model for Rubinstein Taybi Syndrome in zebrafishSemantic proximity Read ↗

The Myb-p300-CREB axis modulates intestine homeostasis, radiosensitivity and tumorigenesis.Semantic proximity Read ↗

Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 ProteinsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.